Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor

Danique L van den Kerkhof, Magdolna Nagy, Kanin Wichapong, Sanne L N Brouns, Dennis P L Suylen, Tilman M Hackeng, I Dijkgraaf*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Eptifibatide is an αIIbβ3 inhibitor that is currently used in the clinic. More than 10 scientific communications indicate that eptifibatide has a Lys-Gly-Asp or Arg-Gly-Asp sequence, while it actually has a hArg-Gly-Asp sequence. We aimed to unravel the importance of the homoarginine residue in eptifibatide in platelet activation and aggregation. Arg- and Lys-eptifibatide were synthesized by solid-phase peptide synthesis and measured in light transmission aggregometry, flow cytometry and whole blood thrombus formation under flow. Interactions of eptifibatide and its variants with αIIbβ3 integrin were studied using molecular dynamics simulations. Eptifibatide showed inhibition of collagen- and ADP-induced platelet aggregation, while Arg- and Lys-eptifibatide did not. Multiparameter assessment of thrombus formation showed suppressed platelet aggregate and fibrin formation upon eptifibatide treatment, in contrast to the other variants. Molecular dynamics simulations revealed that the hArg residue in eptifibatide is crucial to its activity, since the substitution of the hArg to Arg or Lys resulted in the inability to form double H-bonds with Asp224 in the αIIb chain of the αIIbβ3 receptor. The hArg is pivotal for the interaction of eptifibatide for the αIIbβ3 receptor and efficient inhibition of platelet aggregation.

Original languageEnglish
Pages (from-to)96-103
Number of pages8
JournalThrombosis Research
Volume217
DOIs
Publication statusPublished - Sept 2022

Keywords

  • Blood Platelets/metabolism
  • Eptifibatide/pharmacology
  • Homoarginine/metabolism
  • Humans
  • Peptides/metabolism
  • Platelet Aggregation
  • Platelet Aggregation Inhibitors/pharmacology
  • Platelet Glycoprotein GPIIb-IIIa Complex/metabolism
  • Thrombosis/drug therapy
  • DESIGN
  • Cyclic peptides
  • Homoarginine
  • PLATELET
  • Platelet aggregation
  • Eptifibatide
  • GLYCOPROTEIN IIB/IIIA INHIBITORS
  • Platelet aggregation inhibitors
  • ANTAGONISTS

Cite this